Your browser doesn't support javascript.
loading
Osteosarcoma-enriched transcripts paradoxically generate osteosarcoma-suppressing extracellular proteins.
Li, Kexin; Huo, Qingji; Dimmitt, Nathan H; Qu, Guofan; Bao, Junjie; Pandya, Pankita H; Saadatzadeh, M Reza; Bijangi-Vishehsaraei, Khadijeh; Kacena, Melissa A; Pollok, Karen E; Lin, Chien-Chi; Li, Bai-Yan; Yokota, Hiroki.
Affiliation
  • Li K; Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin, China.
  • Huo Q; Department of Biomedical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, United States.
  • Dimmitt NH; Department of Pharmacology, School of Pharmacy, Harbin Medical University, Harbin, China.
  • Qu G; Department of Biomedical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, United States.
  • Bao J; Department of Biomedical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, United States.
  • Pandya PH; Department of Orthopedic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
  • Saadatzadeh MR; Department of Orthopedic Surgery, Harbin Medical University Cancer Hospital, Harbin, China.
  • Bijangi-Vishehsaraei K; Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, United States.
  • Kacena MA; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, United States.
  • Pollok KE; Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, United States.
  • Lin CC; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, United States.
  • Li BY; Department of Pediatric Hematology and Oncology, Indiana University School of Medicine, Indianapolis, United States.
  • Yokota H; Indiana University Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, United States.
Elife ; 122023 03 21.
Article in En | MEDLINE | ID: mdl-36943734
ABSTRACT
Osteosarcoma (OS) is the common primary bone cancer that affects mostly children and young adults. To augment the standard-of-care chemotherapy, we examined the possibility of protein-based therapy using mesenchymal stem cells (MSCs)-derived proteomes and OS-elevated proteins. While a conditioned medium (CM), collected from MSCs, did not present tumor-suppressing ability, the activation of PKA converted MSCs into induced tumor-suppressing cells (iTSCs). In a mouse model, the direct and hydrogel-assisted administration of CM inhibited tumor-induced bone destruction, and its effect was additive with cisplatin. CM was enriched with proteins such as calreticulin, which acted as an extracellular tumor suppressor by interacting with CD47. Notably, the level of CALR transcripts was elevated in OS tissues, together with other tumor-suppressing proteins, including histone H4, and PCOLCE. PCOLCE acted as an extracellular tumor-suppressing protein by interacting with amyloid precursor protein, a prognostic OS marker with poor survival. The results supported the possibility of employing a paradoxical strategy of utilizing OS transcriptomes for the treatment of OS.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Osteosarcoma / Mesenchymal Stem Cells Type of study: Prognostic_studies Limits: Animals Language: En Journal: Elife Year: 2023 Type: Article Affiliation country: China

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Osteosarcoma / Mesenchymal Stem Cells Type of study: Prognostic_studies Limits: Animals Language: En Journal: Elife Year: 2023 Type: Article Affiliation country: China